内脂素在多囊卵巢综合征中的研究进展

Visfatin as a Potential Target in Polycystic Ovary Syndrome

多囊卵巢综合征(PCOS)是一种常见的女性生殖功能障碍与糖代谢异常相关的内分泌紊乱综合征。内脂素是脂肪因子家族新成员,近年研究发现,内脂素在PCOS患者血浆中的表达升高,尤其在肥胖和胰岛素抵抗(IR)的患者中升高更为明显;内脂素在子宫内膜癌患者的血浆和内膜组织中的表达增加,肥胖和IR能增加患子宫内膜癌的风险,而子宫内膜癌是PCOS的远期并发症之一。内脂素与PCOS中的IR、肥胖及远期并发症子宫内膜病变的发生密切相关,内脂素可能是治疗PCOS的新靶点,为研究IR、PCOS提供新的思路。

Polycystic ovary syndrome （PCOS）, a common female reproductive dysfunction, is a endocrine disorder related with glycometabolism. Visfatin is a new member of the adipocytokine family. The level of serum visfatin was found to be higher in PCOS patients, expecially in those PCOS patients with obesity and insulin resistance （IR）. The levels of visfatin were also increased in the serum samples and endometrial tissues of endometrial cancer. The risk of endometrial cancer was increased in those patients with obesity and IR, while the endometrial cancer was thought as one of the long-term complications of PCOS. Visfatin was closely related to IR, obesity and the long-term complications of endometrial lesions in PCOS. Visfatin may be a new potential target for the PCOS treatment and further study.